According to filings with the U.S. Securities and Exchange Commission, Astrin Biosciences is raising up to $22,948,872.00 in new funding. Sources indicate that as part of senior management President, Jayant Parthasarathy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Astrin Biosciences
At Astrin, we know that to win the fight against cancer, we must think big and act boldly. It is with this pioneering spirit that we have developed our breakthrough deep learning-empowered 3D holographic imaging platform for early cancer detection. Our patented platform utilizes Deep Learning and 3D Holographic Imaging to analyze individual cells and, for the first time, has revealed accurate proteomic insights missed using current non-cell-based approaches. Early cancer detection and treatment is the best defense against cancer mortality… and finding cancer early has never been more critical. In recent years, there has been a fundamental shift in our understanding of how cancer progresses as a disease. Conventional thinking suggests that cancer cells spread once a tumor has formed. However, recent studies have revealed that cancer cells actually disseminate into the bloodstream before the primary tumor has been discovered and lay dormant only to re-emerge years later in another area of the body. This could explain one reason patients who initially appear cancer-free after a long and difficult battle later present with cancer.

To learn more about Astrin Biosciences, visit http://astrinbio.com/
Company Linkedin Page: https://www.linkedin.com/company/astrin-biosciences/

Contact:
Jayant Parthasarathy, President
612-212-4102
https://www.linkedin.com/in/jayantparthasarathy/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.